title: New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications.
abstract: Alcohol withdrawal syndrome (AWS) can be a life-threatening condition affecting some alcohol-dependent patients who abruptly discontinue or decrease their alcohol consumption. The main objectives of the clinical management of AWS include: to decrease the severity of symptoms, prevent more severe withdrawal clinical manifestations and facilitate entry of the patient into a treatment program in order to attempt to achieve and maintain long-term abstinence from alcohol. At present, benzodiazepines represent the drugs of choice in the treatment of AWS. However, in line with the possible side effects and addictive properties related to benzodiazepine use, there is growing evidence to suggest that non-benzodiazepine GABAergic compounds represent promising medications in the treatment of alcohol-dependent patients. This review focuses on research into non-benzodiazepine GABAergic medications for the treatment of AWS. Among them, carbamazepine, gabapentin and valproic acid are the most studied. The studies on carbamazepine seem to be the most compelling. Preliminary data have also suggested the possible utility of baclofen and topiramate, although further evidence is needed. The promising results in terms of both safety and efficacy are reported. However, we also note the need of more methodologically controlled studies on a greater number of patients, involving more complicated forms of AWS.
authors.affiliation: Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University Medical School, Providence, RI 02912, USA. Lorenzo_Leggio@brown.edu
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Leggio
authors.forename: George A
authors.initials: GA
authors.lastname: Kenna
authors.forename: Robert M
authors.initials: RM
authors.lastname: Swift
mesh_terms: D020751:Alcohol-Induced Disorders / Q000188:drug therapy*; D000818:Animals; D001569:Benzodiazepines / Q000627:therapeutic use; D018682:GABA Agents / Q000627:therapeutic use*; D006801:Humans; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
chemical_list: D018682:GABA Agents; D001569:Benzodiazepines